mRNA COVID-19 vaccines: science versus misinformation
- Jeff Coller1,2,
- Andrew Geall1,3,
- Roberta Duncan1,
- Clay Alspach1,
- Sean Ryder4,
- Melissa J. Moore4 and
- Fátima Gebauer5,6
- 1The Alliance for mRNA Medicines, Washington, DC 20001, USA
- 2RNA Innovation Center, Johns Hopkins University, Baltimore, Maryland 21218, USA
- 3Replicate Bioscience, San Diego, California 92121, USA
- 4Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01655, USA
- 5Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona 08003, Spain
- 6Universitat Pompeu Fabra (UPF), Barcelona 08003, Spain
- Corresponding author: jmcoller{at}jhmi.edu
Abstract
The rapid development of COVID-19 vaccines as a result of Operation Warp Speed represented an extraordinary triumph of scientific innovation, with multiple vaccine platforms demonstrating remarkable efficacy in preventing severe disease, hospitalization, and death—ultimately saving millions of lives. The U.S. government, pharmaceutical companies, research institutions, and health agencies collaborated at an unprecedented scale to develop, test, and distribute vaccines, showcasing what coordinated medical innovation can accomplish. Vaccination programs successfully prevented catastrophic outcomes and enabled people to return to normal life during the crisis. COVID-19 vaccines continue to provide critical protection for vulnerable populations today, and the mRNA platforms developed have opened new possibilities for treating cancers and other diseases. Yet despite rigorous regulatory oversight and extensive clinical trial data, these vaccines have faced substantial misinformation campaigns that spread false claims about their safety and design. To address these misrepresentations and resultant public concerns, this document draws on rigorous scientific evidence to comprehensively examine the misconceptions surrounding mRNA technology, explaining how these vaccines work, their proven safety record, and their demonstrated benefits.
Keywords
This article, published in RNA, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
